Checkpoint Therapeutics jumps

Fierce Pharma Asia—Takeda's oncology focus; Sun's Checkpoint buy; Ono-Ionis antisense deal
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an FDA-approved PD-L1 inhibitor. | Takeda is sharpening its oncology focus amid an R&D revamp.
Checkpoint Therapeutics jumps after deal to be acquired by Sun Pharma
Shares of Checkpoint Therapeutics (CKPT) have jumped $1.59, or 64%, to $4.06 in Monday morning trading after the company and Sun Pharmaceutical
Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma
Shares of Checkpoint Therapeutics surged in premarktet trading Monday after the immunotherapy and targeted oncology company agreed to be acquired by Indian pharmaceutical giant Sun Pharmaceutical Industries.
Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.
Sun Pharma to acquire Checkpoint Therapeutics
Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology treatments, for an aggregate upfront price of $355m. The acquisition is set to add Checkpoint's US Food and Drug Administration (FDA)-approved Unloxcyt (cosibelimab-ipdl) to the global onco-derm franchise of Sun Pharma.
Sun Pharma to acquire US oncology compony for over Rs 3,000 crore
Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma's specialty portfolio, including UNLOXCYT,
India's Sun Pharma buys onco-derma firm Checkpoint Therapeutics for $355M
India's pharma giant Sun Pharma is to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted oncology company—for an upfront cash payment o
Fintel on MSN3d
HC Wainwright & Co. Downgrades Checkpoint Therapeutics (CKPT)
Fintel reports that on March 11, 2025, HC Wainwright & Co. downgraded their outlook for Checkpoint Therapeutics ...
India's Sun Pharma to acquire Checkpoint Therapeutics for $355 million
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and ...
HC Wainwright Reaffirms Neutral Rating for Checkpoint Therapeutics (NASDAQ:CKPT)
Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “neutral” rating reissued by research analysts at HC ...
Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...
Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Cartesian Therapeutics (RNAC)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on PDS Biotechnology (PDSB – Research Report) and Cartesian ...
Checkpoint Therapeutics’ (CKPT) Hold Rating Reaffirmed at Lake Street Capital
Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report)‘s stock had its “hold” rating reiterated by equities research ...
Labiotech.eu2d
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkpoint Therapeutics, Inc. Buyout
Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities ...